Blackstone Life Sciences will invest $250 million into Anagram Therapeutics to target the complication burden of cystic fibrosis. The company’s approach is aimed at reducing the daily pill load for patients with exocrine pancreatic insufficiency, where current regimens can require up to dozens of pills per day. Anagram positions its program around improving treatment practicality—specifically moving toward a regimen that could shrink administration to a small number of pills daily. The investment underlines continued appetite for CF-adjacent efforts focused on adherence and real-world treatment burden. With Blackstone putting fresh capital behind Anagram’s therapeutic strategy, the deal also signals that investors are still willing to fund late-stage translational work when the target is a measurable patient-impact metric like daily dosing complexity. The funding came as the portfolio activity continues across rare disease therapeutics, where commercialization challenges often hinge on dosing regimens and patient acceptance as much as on clinical efficacy.